Harmony Biosciences Inc.
HRMY | NASDAQ
$42.02
-$0.08 (-0.19%)
Sep 22, 2026, 12:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 868.45M | 714.73M | 582.02M | 437.86M | 305.44M | 159.74M |
Cost of Revenue | 198.34M | 156.82M | 121.24M | 83.48M | 55.52M | 27.74M |
Gross Profit | 670.11M | 557.92M | 460.79M | 354.37M | 249.92M | 132M |
Operating Income | 208.47M | 190.83M | 192.03M | 120.19M | 87.53M | 16.99M |
Interest Income | 21.92M | 18.54M | 14.73M | 3.13M | 224K | n/a |
Pretax Income | 215.06M | 191.8M | 173.4M | 104.69M | 37.43M | -36.94M |
Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.6M | -36.94M |
Selling & General & Admin | 272.05M | 221.27M | 192.69M | 163.3M | 132.03M | 95.57M |
Research & Development | 189.59M | 145.83M | 76.06M | 70.89M | 30.37M | 19.45M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 461.64M | 367.09M | 268.76M | 234.19M | 162.39M | 115.02M |
Interest Expense | 14.65M | 17.5M | 23.76M | 18.8M | 24.19M | 28.22M |
Selling & Marketing Expenses | 119.51M | 110.92M | 97.4M | 79.29M | 68.12M | 55.82M |
Cost & Expenses | 659.98M | 523.91M | 389.99M | 317.67M | 217.91M | 142.76M |
Income Tax Expense | 56.38M | 46.31M | 44.54M | -76.78M | 2.83M | n/a |
Shares Outstanding (Basic) | 57.49M | 56.89M | 59.47M | 59.17M | 57.53M | 56.89M |
Shares Outstanding (Diluted) | 58.54M | 57.87M | 60.37M | 61.1M | 59.21M | 57.85M |
EPS (Basic) | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -1.12 |
EPS (Diluted) | 2.71 | 2.51 | 2.13 | 2.97 | 0.58 | -1.10 |
EBITDA | 255.05M | 233.41M | 221.51M | 146.87M | 80.46M | 1.51M |
EBIT | 229.71M | 209.3M | 197.15M | 123.48M | 61.62M | -8.72M |
Depreciation & Amortization | 25.34M | 24.11M | 24.36M | 23.39M | 18.84M | 10.24M |
Add to Watchlist
Select watchlists to add or remove HRMY